Skip to main content
Premium Trial:

Request an Annual Quote

Genaissance Shares Climb 7.6 Percent On News of Animal-genotyping Alliance

NEW YORK, Dec. 3 (GenomeWeb News) - Shares in Genaissance Pharmaceuticals were up 7.64 percent at $1.69 in mid-afternoon trading one day after the company announced an animal-genotyping collaboration with a British company.

Yesterday, Genaissance said it will use its HAP technology platform perform genotyping studies on three undisclosed meat animal species provided by Sygen International.

UK-based Sygen is an animal-breeding concern, which has two subsidiaries. One provides breeding stock to the North American pork industry, and the other supplies shrimp for cultivation.

Terms of the agreement were not disclosed.

The Scan

UCLA Team Reports Cost-Effective Liquid Biopsy Approach for Cancer Detection

The researchers report in Nature Communications that their liquid biopsy approach has high specificity in detecting all- and early-stage cancers.

Machine Learning Improves Diagnostic Accuracy of Breast Cancer MRI, Study Shows

Combining machine learning with radiologists' interpretations further increased the diagnostic accuracy of MRIs for breast cancer, a Science Translational Medicine paper finds.

Genome Damage in Neurons Triggers Alzheimer's-Linked Inflammation

Neurons harboring increased DNA double-strand breaks activate microglia to lead to neuroinflammation like that seen in Alzheimer's disease, a new Science Advances study finds.

Long COVID-19 Susceptibility Clues Contained in Blood Plasma Proteome

A longitudinal study in eBioMedicine found weeks-long blood plasma proteome shifts after SARS-CoV-2 infection, along with proteomic signatures that appeared to coincide with long Covid risk.